Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer

In TROPiCS-02, sacituzumab govitecan (SG) demonstrated significantly longer overall survival and progression-free survival with improved quality of life vs. chemotherapy treatment of physician’s choice (TPC) in patients with HR+/HER2− metastatic breast cancer (mBC). The safety profile was consistent...

Full description

Saved in:
Bibliographic Details
Main Authors: Hope S. Rugo, Aditya Bardia, Peter Schmid, Sara M. Tolaney, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Marine Gosset, Adam Brufsky, Javier Cortés, Frederik Marmé
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Current Oncology
Subjects:
quality of life
Q-TWiST
breast cancer
HR+/HER2−
antibody-drug conjugate
sacituzumab govitecan
Online Access:https://www.mdpi.com/1718-7729/32/3/169
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/3/169

Similar Items